Depletion of CXCR2 inhibits @c-secretase activity and amyloid-@b production in a murine model of Alzheimer's disease
Alzheimer's disease (AD) is a neurodegenerative disorder that leads to progressive cognitive decline. Recent studies from our group and others have suggested that certain G-protein coupled receptors (GPCRs) can influence the processing of the amyloid precursor protein (APP). Earlier, we demonstrated that stimulation of a chemokine receptor, CXCR2, results in enhanced @c-secretase activity and in increased amyloid-beta (A@b) production. Taken together, results obtained from in vitro studies indicate that therapeutic targeting of CXCR2 might aid in lowering A@b levels in the AD brain. To better understand the precise function and to predict the consequences of CXCR2 depletion in the AD brain, we have crossed CXCR2 knockout mice with mice expressing presenilin (PS1 M146L) and APPsw mutations (PSAPP). Our present study confirms that CXCR2 depletion results in reduction of A@b with concurrent increases of @c-secretase substrates. At the mechanistic level, the effect of CXCR2 on @c-secretase was not found to occur via their direct interaction. Furthermore, we provide evidence that A@b promotes endocytosis of CXCR2 via increasing levels of CXCR2 ligands. In conclusion, our current study confirms the regulatory role of CXCR2 in APP processing, and poses it as a potential target for developing novel therapeutics for intervention in AD.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Version: za2963e q8za6 q8zb5 q8zca q8zdd q8zeb q8zf6 q8zg5